Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|July 28, 2021
Pre-Filled Syringes
Author(s)Pfizer CentreOne
With the support of our dedicated experts, Pfizer CentreOne can help your product scale up to commercial and reliably deliver your product to your patients under the highest quality standards for which Pfizer stands for.
The complex nature of modern drug substances and the potential interaction between the drug and the packaging material are some of the major challenges developers deal with when working with such products.
Pfizer CentreOne is in a unique position to offer you Pfizer’s experience in the development and commercial manufacture of pre-filled syringes. With the support of our dedicated experts, we can help your product scale up to commercial and reliably deliver your product to your patients under the highest quality standards for which Pfizer stands for.
Our Offering
- Scale up and optimization
- Commercial supply
- Expertise with small molecule and biologics
- Packaging
- Regulatory Affairs services
Let’s Collaborate.
For more information, you can read more at
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.